JD Supra17d
Teva v. Amneal Ruling Interprets Orange Book Listing Statute, Affirms Delisting of Device Patents
On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...
JD Supra25d
CAFC Decision on Orange Book Listings for Drug/Device Combination Patents
Patentees and sponsors of New Drug Applications (NDAs ... to market and sell an inhaler device that administers the API albuterol sulfate. Teva listed several patents in the OB for ProAir ...
Federal Register25d
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
CNN27d
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...
USA Today27d
FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.
The National Law Review28d
Federal Circuit Decides Case Involving Orange Book Listing of Device Patents
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...